Autolus Therapeutics (NASDAQ:AUTL) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a report published on Thursday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

Other equities analysts have also issued reports about the company. Wells Fargo & Company decreased their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 21st. Truist Financial cut their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $9.32.

Autolus Therapeutics Stock Down 1.4%

Shares of Autolus Therapeutics stock opened at $2.12 on Thursday. The firm has a market cap of $564.22 million, a P/E ratio of -1.75 and a beta of 1.76. Autolus Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $5.00. The business has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.95.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $8.98 million during the quarter, compared to the consensus estimate of $1.59 million. As a group, equities research analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Hedge funds have recently modified their holdings of the business. Candriam S.C.A. acquired a new position in shares of Autolus Therapeutics in the fourth quarter worth $7,500,000. AXA S.A. bought a new position in shares of Autolus Therapeutics in the fourth quarter worth about $4,288,000. Armistice Capital LLC increased its stake in shares of Autolus Therapeutics by 19.6% in the first quarter. Armistice Capital LLC now owns 11,000,000 shares of the company’s stock worth $17,050,000 after purchasing an additional 1,800,000 shares during the period. Wellington Management Group LLP increased its stake in shares of Autolus Therapeutics by 6.9% in the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock worth $41,992,000 after purchasing an additional 1,746,020 shares during the period. Finally, Millennium Management LLC grew its position in Autolus Therapeutics by 91.6% during the fourth quarter. Millennium Management LLC now owns 1,653,241 shares of the company’s stock worth $3,885,000 after buying an additional 790,437 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.